Bringing Value to the Healthcare Community

Our fundamental mission is to make the lives of patients better. We listen, we take the time to understand, and through meaningful and impactful partnerships, we aim to create a lasting difference.

Patient Access

The complexity of biologic medicines makes them expensive to produce, placing a high cost on the healthcare system. The utilization of high-quality, lower cost biosimilars can improve the sustainability of healthcare systems, providing the potential for more patients to benefit from biological medicines.

We are leveraging our pharmaceutical expertise in parallel tracks. Through novel biologics and biosimilar programs, we hope to increase the availability of safe, effective, high-quality therapeutic options to patients worldwide.

Benefit of reduced cost to healthcare system

The RAND Corporation has projected that the use of biosimilar medicines in the US will reduce direct spending on biologics by $54 billion from 2017 to 2026.

In the US, in 2021, biosimilars generated $7 billion in savings for patients and the healthcare system.¹² Since the first biosimilar was approved in the US in 2015, biosimilar medicines have generated more than $13 billion in savings.¹²

Collaboration

Boehringer Ingelheim believes that new advances in biologic treatments and processes can be achieved by partnering with healthcare professionals, payers, employers and patient associations. Working together, we can deliver solutions that bring value to the entire healthcare community and improve the treatment journey of our patients with their biologic medicines.

Organizational partnerships

We are also proud to partner with and be a founding member of several organizations committed to raising biosimilar awareness, education and access, including the Biosimilars Forum and the Biologics and Biosimilars Collective Intelligence Consortium.

Advocacy

Boehringer Ingelheim is proud of the role we play in raising public awareness of biosimilars as well as the importance of stimulating a competitive marketplace to bring more affordable treatment options to US patients. 

Through key partnerships with organizations like the Crohn’s and Colitis Foundation, The Arthritis Foundation, and the National Psoriasis Foundation, we are able to leverage their expertise and develop educational materials that resonate with patients and healthcare providers, ultimately driving access to these important treatments.  

Advocating for increased access to biosimilars

Boehringer Ingelheim is supportive of progressive reimbursement and market access policies that will bolster adoption and access of biosimilars in the U.S. market. We believe that incentives across all stakeholders including patients, physicians and health plans must be created to stimulate biosimilar utilization. We support policies across federal programs to implement these incentives.

Filing of Citizen Petition

Boehringer Ingelheim has filed a Citizen Petition asking FDA to correct its interpretation of the term “strength” as used in the Biologics Price Competition and Innovation Act (BPCIA).

Boehringer Ingelheim believes the actions requested in this petition will benefit patients and the US healthcare system, potentially leading to more robust biosimilar development and use, and reduce anti-competitive behavior within the biosimilars industry.